{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:07:19Z","timestamp":1784948839123,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009827","name":"Alexandria University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009827","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes Coronavirus disease 2019 (COVID-19), which is a huge global health threat. Interleukin27 (IL-27) gene is a cytokine that produces antiviral proteins in an IFN-independent manner and stimulates both pro- and anti-inflammatory responses. Interferon induced transmembrane protein 3 (IFITM3) inhibits SARS-CoV2 infection by blocking SARSCoV-2 spike proteins which facilitate viral entrance and cell-to-cell fusion. The association between genetic variants and COVID-19 in Egyptians is still unclear. Hence, we sought to investigate the impact of the single nucleotide polymorphism of IL-27P28 rs153109 and IFITM3 rs12252 on the susceptibility and severity of SARS-CoV-2 in Egyptian patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Our study included 242 SARS-CoV-2 patients were recruited from Main University Hospital, Alexandria University, Egypt, and 187 healthy controls. We subdivided the patient group into two subgroups: group A comprised mild\/moderate cases (N\u2009=\u200942) (17.4%), and group B included severe\/critical cases (N\u2009=\u2009200) (82.6%). Genomic DNA was extracted from blood samples using the QIAamp DNA Blood Mini kit, then the PCR products of IL27 and IFITM3 were cut by FastDigest XhoI and MScI, respectively, for detection of SNPs of IL-27P28 rs153109 (-964A\/G) and IFITM3 rs12252 (T&gt;C).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The present study found a significant association between IL27 rs153109 (-964A\/G) and SARS-CoV-2 infection susceptibility after adjusting for the risk factor (advanced age), IL27 rs153109 (-964A\/G) AG genotype (OR\u2009=\u20092.791, 95% CI: 1.237\u20136.295, <jats:italic>P<\/jats:italic>\u2009=\u20090.013), AA genotype (OR\u2009=\u20092.385, 95% CI: 1.075\u20135.291, <jats:italic>P<\/jats:italic>\u2009=\u20090.033), and (AG+AA vs. GG) genotypes (OR\u2009=\u20092.558, 95% CI: 1.186\u20135.517, <jats:italic>P<\/jats:italic>\u2009=\u20090.017). On the other hand, the IFITM3 rs12252(T&gt;C) CT genotype (OR\u2009=\u20091.419, 95% CI: 0.843\u20132.391, <jats:italic>P<\/jats:italic>\u2009=\u20090.188), CC genotype (OR\u2009=\u20092.132, 95% CI: 0.436\u201310.415, <jats:italic>P<\/jats:italic>\u2009=\u20090.350), and (C\/T+C\/C vs. TT) genotypes (OR\u2009=\u20091.466, 95% CI: 0.884\u20132.432, <jats:italic>P<\/jats:italic>\u2009=\u20090.138) did not show a statistically significant association with either susceptibility or the severity of SARS-CoV-2.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>IL27P28 rs153109 AG and AA genotypes of IL27 may be associated with the susceptibility of SARS-CoV-2 infection but not the severity. Concerning the IFITM3 rs12252 SNP, we could not confirm its influence on either susceptibility or the severity of SARS-CoV-2 in this Egyptian population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12985-025-02668-z","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T10:44:48Z","timestamp":1741430688000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of single nucleotide polymorphism of IL-27P28 rs153109 and IFITM3 rs12252 on susceptibility and severity of COVID-19 in Egyptian patients: a case control study"],"prefix":"10.1186","volume":"22","author":[{"given":"Hanan","family":"Hamdy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem H.","family":"Elhamammy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Abdelmageed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3613-2796","authenticated-orcid":false,"given":"Ahmed","family":"Wahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"issue":"1","key":"2668_CR1","first-page":"20","volume":"529","author":"R Ochani","year":"2021","unstructured":"Ochani R, Asad A, Yasmin F, Shaikh S, Khalid H, Batra S, et al. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infez Med. 2021;529(1):20\u201336.","journal-title":"Infez Med."},{"key":"2668_CR2","unstructured":"World Health Organization. https:\/\/data.who.int\/dashboards\/covid19\/cases?n=c. Accessed 16 Jan 2025."},{"key":"2668_CR3","unstructured":"World Health Organization Egypt. https:\/\/data.who.int\/dashboards\/covid19\/cases?m49=818&n=c. Accessed 16 Jan 2025."},{"issue":"10223","key":"2668_CR4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507\u201313.","journal-title":"Lancet"},{"issue":"7","key":"2668_CR5","doi-asserted-by":"publisher","first-page":"e0270627","DOI":"10.1371\/journal.pone.0270627","volume":"17","author":"C Dieter","year":"2022","unstructured":"Dieter C, Brondani LA, Leit\u00e3o CB, Gerchman F, Lemos NE, Crispim D. Genetic polymorphisms associated with susceptibility to COVID-19 disease and severity: a systematic review and meta-analysis. PLoS ONE. 2022;17(7):e0270627.","journal-title":"PLoS ONE"},{"issue":"6","key":"2668_CR6","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1074-7613(02)00324-2","volume":"16","author":"S Pflanz","year":"2002","unstructured":"Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 2002;16(6):779\u201390.","journal-title":"Immunity"},{"issue":"1","key":"2668_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1006\/bbrc.1998.8576","volume":"246","author":"CA Sprecher","year":"1998","unstructured":"Sprecher CA, Grant FJ, Baumgartner JW, Presnell SR, Schrader SK, Yamagiwa T, et al. Cloning and characterization of a novel class I cytokine receptor. Biochem Biophys Res Commun. 1998;246(1):82\u201390.","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"2668_CR8","first-page":"178","volume":"168","author":"JF Vald\u00e9s-L\u00f3pez","year":"2023","unstructured":"Vald\u00e9s-L\u00f3pez JF, Urcuqui-Inchima S. Antiviral response and immunopathogenesis of interleukin 27 in COVID-19. Adv Virol. 2023;168(7):178.","journal-title":"Adv Virol"},{"issue":"1","key":"2668_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s13054-018-2180-0","volume":"22","author":"J He","year":"2018","unstructured":"He J, Zhang Q, Zhang W, Chen F, Zhao T, Lin Y, et al. The interleukin-27 -964A>G polymorphism enhances sepsis-induced inflammatory responses and confers susceptibility to the development of sepsis. Critical Care. 2018;22(1):248.","journal-title":"Critical Care"},{"issue":"4","key":"2668_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10038-007-0123-8","volume":"52","author":"SC Chae","year":"2007","unstructured":"Chae SC, Li CS, Kim KM, Yang JY, Zhang Q, Lee YC, et al. Identification of polymorphisms in human interleukin-27 and their association with asthma in a Korean population. J Hum Genet. 2007;52(4):355\u201361.","journal-title":"J Hum Genet"},{"issue":"9","key":"2668_CR11","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.humimm.2014.07.004","volume":"75","author":"Y Shen","year":"2014","unstructured":"Shen Y, Yuan X-D, Hu D, Ke X, Wang X-Q, Hu G-H, et al. Association between Interleukin-27 gene polymorphisms and susceptibility to allergic rhinitis. Hum Immunol. 2014;75(9):991\u20135.","journal-title":"Hum Immunol"},{"issue":"9","key":"2668_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1089\/dna.2007.0715","volume":"27","author":"N Huang","year":"2008","unstructured":"Huang N, Liu L, Wang XZ, Liu D, Yin SY, Yang XD. Association of interleukin (IL)-12 and IL-27 gene polymorphisms with chronic obstructive pulmonary disease in a Chinese population. DNA Cell Biol. 2008;27(9):527\u201331.","journal-title":"DNA Cell Biol"},{"key":"2668_CR13","doi-asserted-by":"publisher","first-page":"155354","DOI":"10.1016\/j.cyto.2020.155354","volume":"137","author":"J G\u00f3mez","year":"2021","unstructured":"G\u00f3mez J, Albaiceta GM, Cuesta-Llavona E, Garc\u00eda-Clemente M, L\u00f3pez-Larrea C, Amado-Rodr\u00edguez L, et al. The Interferon-induced transmembrane protein 3 gene (IFITM3) rs12252 C variant is associated with COVID-19. Cytokine. 2021;137:155354.","journal-title":"Cytokine"},{"issue":"4","key":"2668_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/imm.13163","volume":"159","author":"DC Y\u00e1nez","year":"2020","unstructured":"Y\u00e1nez DC, Ross S, Crompton T. The IFITM protein family in adaptive immunity. Immunology. 2020;159(4):365\u201372.","journal-title":"Immunology"},{"issue":"3","key":"2668_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.cyto.2008.07.009","volume":"43","author":"S Koyama","year":"2008","unstructured":"Koyama S, Ishii KJ, Coban C, Akira S. Innate immune response to viral infection. Cytokine. 2008;43(3):336\u201341.","journal-title":"Cytokine"},{"issue":"10","key":"2668_CR16","doi-asserted-by":"publisher","first-page":"e1002337","DOI":"10.1371\/journal.ppat.1002337","volume":"7","author":"EM Feeley","year":"2011","unstructured":"Feeley EM, Sims JS, John SP, Chin CR, Pertel T, Chen LM, et al. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog. 2011;7(10):e1002337.","journal-title":"PLoS Pathog"},{"issue":"7","key":"2668_CR17","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.cell.2009.12.017","volume":"139","author":"AL Brass","year":"2009","unstructured":"Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell. 2009;139(7):1243\u201354.","journal-title":"Cell"},{"issue":"9","key":"2668_CR18","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.3390\/v6093683","volume":"6","author":"F Wrensch","year":"2014","unstructured":"Wrensch F, Winkler M, P\u00f6hlmann S. IFITM proteins inhibit entry driven by the MERS-coronavirus spike protein: evidence for cholesterol-independent mechanisms. Viruses. 2014;6(9):3683\u201398.","journal-title":"Viruses"},{"issue":"7395","key":"2668_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature10921","volume":"484","author":"AR Everitt","year":"2012","unstructured":"Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature. 2012;484(7395):519\u201323.","journal-title":"Nature"},{"key":"2668_CR20","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1017\/S0950268818002832","volume":"147","author":"T Chen","year":"2018","unstructured":"Chen T, Xiao M, Yang J, Chen YK, Bai T, Tang XJ, et al. Association between rs12252 and influenza susceptibility and severity: an updated meta-analysis. Epidemiol Infect. 2018;147:e39.","journal-title":"Epidemiol Infect"},{"issue":"9\u201310","key":"2668_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00251-020-01188-0","volume":"72","author":"YC Kim","year":"2020","unstructured":"Kim YC, Jeong BH. Ethnic variation in risk genotypes based on single nucleotide polymorphisms (SNPs) of the interferon-inducible transmembrane 3 (IFITM3) gene, a susceptibility factor for pandemic 2009 H1N1 influenza A virus. Immunogenetics. 2020;72(9\u201310):447\u201353.","journal-title":"Immunogenetics"},{"issue":"6","key":"2668_CR22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.molcel.2010.08.011","volume":"39","author":"V Tripathi","year":"2010","unstructured":"Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39(6):925\u201338.","journal-title":"Mol Cell"},{"issue":"1","key":"2668_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s43168-022-00116-y","volume":"16","author":"NE Zayed","year":"2022","unstructured":"Zayed NE, Abbas A, Lutfy SM. Criteria and potential predictors of severity in patients with COVID-19. Egypt J Bronchol. 2022;16(1):11.","journal-title":"Egypt J Bronchol"},{"issue":"2","key":"2668_CR24","first-page":"028","volume":"1","author":"S Wang","year":"2009","unstructured":"Wang S, Zhu C, Zhang R, Liu L, Wu J. Association of interleukin 27 expression and p28 gene polymorphism with chronic hepatitis B virus infection. J Toxicol Environ Health Sci. 2009;1(2):028\u201333.","journal-title":"J Toxicol Environ Health Sci"},{"issue":"1","key":"2668_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejmhg.2013.12.001","volume":"15","author":"YBM Ali","year":"2014","unstructured":"Ali YBM, El-Masry SA, El-Akhras BA, El-Shenawy SZ, El-Sayed IH. Association of Interleukin 27 gene polymorphism and risk of Hepatitis B viral infection in Egyptian population. Egypt J Med Human Gen. 2014;15(1):53\u20139.","journal-title":"Egypt J Med Human Gen"},{"issue":"4","key":"2668_CR26","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.7314\/APJCP.2016.17.4.2093","volume":"17","author":"MM Fawzy","year":"2016","unstructured":"Fawzy MM, Wahid A, Nazmy MH, Hashem M, Waked I, Abdelwahab SF. Association of interleukin-27 rs 153109 single nucleotide polymorphism with spontaneous resolution of hepatitis C virus - genotype 4a infection in Egyptian patients. Asian Pac J Cancer Prev: APJCP. 2016;17(4):2093\u20137.","journal-title":"Asian Pac J Cancer Prev: APJCP"},{"issue":"3","key":"2668_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/08820139.2018.1510958","volume":"48","author":"E Tharwat","year":"2019","unstructured":"Tharwat E, Gad GFM, Nazmy MH, Mohamed HI, Hamza N, Wahid A, et al. Impact of IL-27p28 (rs153109) and TNF-\u03b1 (rs1800629) genetic polymorphisms on the progression of HCV infection in egyptian patients. Immunol Invest. 2019;48(3):255\u201367.","journal-title":"Immunol Invest"},{"issue":"7","key":"2668_CR28","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1093\/infdis\/jit468","volume":"209","author":"TC Mills","year":"2014","unstructured":"Mills TC, Rautanen A, Elliott KS, Parks T, Naranbhai V, Ieven MM, et al. IFITM3 and susceptibility to respiratory viral infections in the community. J Infect Dis. 2014;209(7):1028\u201331.","journal-title":"J Infect Dis"},{"issue":"15","key":"2668_CR29","doi-asserted-by":"publisher","first-page":"15730","DOI":"10.18632\/aging.103803","volume":"12","author":"F He","year":"2020","unstructured":"He F, Luo Q, Lei M, Fan L, Shao X, Huang G, et al. Risk factors for severe cases of COVID-19: a retrospective cohort study. Aging. 2020;12(15):15730\u201340.","journal-title":"Aging"},{"issue":"5","key":"2668_CR30","doi-asserted-by":"publisher","first-page":"2000524","DOI":"10.1183\/13993003.00524-2020","volume":"55","author":"RH Du","year":"2020","unstructured":"Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55(5):2000524.","journal-title":"Eur Respir J"},{"key":"2668_CR31","first-page":"91","volume":"94","author":"J Yang","year":"2020","unstructured":"Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis: IJID: Official Publ Int Soc Infect Dis. 2020;94:91\u20135.","journal-title":"Int J Infect Dis: IJID: Official Publ Int Soc Infect Dis"},{"issue":"6","key":"2668_CR32","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1111\/tbed.13651","volume":"67","author":"Y Dong","year":"2020","unstructured":"Dong Y, Zhou H, Li M, Zhang Z, Guo W, Yu T, et al. A novel simple scoring model for predicting severity of patients with SARS-CoV-2 infection. Transbound Emerg Dis. 2020;67(6):2823\u20139.","journal-title":"Transbound Emerg Dis"},{"key":"2668_CR33","doi-asserted-by":"publisher","first-page":"394632022111531","DOI":"10.1177\/03946320221115316","volume":"36","author":"G Rasool","year":"2022","unstructured":"Rasool G, Riaz M, Abbas M, Fatima H, Qamar MM, Zafar F, et al. COVID-19: Clinical laboratory diagnosis and monitoring of novel coronavirus infected patients using molecular, serological and biochemical markers: a review. Int J Immunopathol Pharmacol. 2022;36:3946320221115316.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2668_CR34","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2217\/fvl-2020-0316","volume":"16","author":"D Cihakova","year":"2021","unstructured":"Cihakova D, Streiff MB, Menez SP, Chen TK, Gilotra NA, Michos ED, et al. High-value laboratory testing for hospitalized COVID-19 patients: a review. Future Virol. 2021;16:691\u2013705.","journal-title":"Future Virol"},{"issue":"2","key":"2668_CR35","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.advms.2021.07.009","volume":"66","author":"A Zinellu","year":"2021","unstructured":"Zinellu A, Paliogiannis P, Carru C, Mangoni AA. INR and COVID-19 severity and mortality: a systematic review with meta-analysis and meta-regression. Adv Med Sci. 2021;66(2):372\u201380.","journal-title":"Adv Med Sci"},{"issue":"2","key":"2668_CR36","doi-asserted-by":"publisher","first-page":"691","DOI":"10.4049\/jimmunol.1300252","volume":"192","author":"Y Cao","year":"2014","unstructured":"Cao Y, Zhang R, Zhang W, Zhu C, Yu Y, Song Y, et al. IL-27, a cytokine, and IFN-\u03bb1, a type III IFN, are coordinated to regulate virus replication through type I IFN. J Immunol. 2014;192(2):691\u2013703.","journal-title":"J Immunol"},{"issue":"1","key":"2668_CR37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/QAD.0b013e3282f3356c","volume":"22","author":"T Imamichi","year":"2008","unstructured":"Imamichi T, Yang J, Huang DW, Brann TW, Fullmer BA, Adelsberger JW, et al. IL-27, a novel anti-HIV cytokine, activates multiple interferon-inducible genes in macrophages. AIDS. 2008;22(1):39\u201345.","journal-title":"AIDS"},{"issue":"6","key":"2668_CR38","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1089\/jir.2009.0093","volume":"30","author":"AC Frank","year":"2010","unstructured":"Frank AC, Zhang X, Katsounas A, Bharucha JP, Kottilil S, Imamichi T. Interleukin-27, an anti-HIV-1 cytokine, inhibits replication of hepatitis C virus. J Interferon & Cytokine Res: Official J Int Soc Interferon and Cytokine Res. 2010;30(6):427\u201331.","journal-title":"J Interferon & Cytokine Res: Official J Int Soc Interferon and Cytokine Res"},{"issue":"15","key":"2668_CR39","doi-asserted-by":"publisher","first-page":"11899","DOI":"10.1074\/jbc.M111.308064","volume":"287","author":"L Liu","year":"2012","unstructured":"Liu L, Cao Z, Chen J, Li R, Cao Y, Zhu C, et al. Influenza A virus induces interleukin-27 through cyclooxygenase-2 and protein kinase a signaling. J Biol Chem. 2012;287(15):11899\u2013910.","journal-title":"J Biol Chem"},{"key":"2668_CR40","doi-asserted-by":"publisher","first-page":"44485","DOI":"10.1038\/srep44485","volume":"7","author":"A Garg","year":"2017","unstructured":"Garg A, Trout R, Spector SA. Human immunodeficiency virus type-1 myeloid derived suppressor cells inhibit cytomegalovirus inflammation through interleukin-27 and B7\u2013H4. Sci Rep. 2017;7:44485.","journal-title":"Sci Rep"},{"issue":"10","key":"2668_CR41","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1111\/j.1440-1746.2009.05901.x","volume":"24","author":"CS Li","year":"2009","unstructured":"Li CS, Zhang Q, Lee KJ, Cho SW, Lee KM, Hahm KB, et al. Interleukin-27 polymorphisms are associated with inflammatory bowel diseases in a Korean population. J Gastroenterol Hepatol. 2009;24(10):1692\u20136.","journal-title":"J Gastroenterol Hepatol"},{"key":"2668_CR42","doi-asserted-by":"publisher","first-page":"394632022114582","DOI":"10.1177\/03946320221145827","volume":"36","author":"B Zamani","year":"2022","unstructured":"Zamani B, Najafizadeh M, Motedayyen H, Arefnezhad R. Predicting roles of IL-27 and IL-32 in determining the severity and outcome of COVID-19. Int J Immunopathol Pharmacol. 2022;36:3946320221145827.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"3","key":"2668_CR43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41589-018-0213-2","volume":"15","author":"JS Spence","year":"2019","unstructured":"Spence JS, He R, Hoffmann HH, Das T, Thinon E, Rice CM, et al. IFITM3 directly engages and shuttles incoming virus particles to lysosomes. Nat Chem Biol. 2019;15(3):259\u201368.","journal-title":"Nat Chem Biol"},{"key":"2668_CR44","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/annurev-virology-031413-085537","volume":"1","author":"CC Bailey","year":"2014","unstructured":"Bailey CC, Zhong G, Huang IC, Farzan M. IFITM-family proteins: the cell\u2019s first line of antiviral defense. Ann Rev Virol. 2014;1:261\u201383.","journal-title":"Ann Rev Virol"},{"key":"2668_CR45","doi-asserted-by":"publisher","first-page":"146790","DOI":"10.1016\/j.gene.2022.146790","volume":"844","author":"K Gupta","year":"2022","unstructured":"Gupta K, Kaur G, Pathak T, Banerjee I. Systematic review and meta-analysis of human genetic variants contributing to COVID-19 susceptibility and severity. Gene. 2022;844:146790.","journal-title":"Gene"},{"issue":"4","key":"2668_CR46","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3892\/etm.2023.11857","volume":"25","author":"K Yu","year":"2023","unstructured":"Yu K, Wang J, Li H, Wang W. IFITM3 rs12252 polymorphism and coronavirus disease 2019 severity: a meta-analysis. Exp Ther Med. 2023;25(4):158.","journal-title":"Exp Ther Med"},{"issue":"1","key":"2668_CR47","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/infdis\/jiaa224","volume":"222","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Qin L, Zhao Y, Zhang P, Xu B, Li K, et al. Interferon-induced transmembrane protein 3 genetic variant rs12252-C associated with disease severity in coronavirus disease 2019. J Infect Dis. 2020;222(1):34\u20137.","journal-title":"J Infect Dis"},{"key":"2668_CR48","doi-asserted-by":"publisher","first-page":"155492","DOI":"10.1016\/j.cyto.2021.155492","volume":"142","author":"K Sch\u00f6nfelder","year":"2021","unstructured":"Sch\u00f6nfelder K, Breuckmann K, Elsner C, Dittmer U, Fistera D, Herbstreit F, et al. The influence of IFITM3 polymorphisms on susceptibility to SARS-CoV-2 infection and severity of COVID-19. Cytokine. 2021;142:155492.","journal-title":"Cytokine"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02668-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02668-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02668-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T11:07:49Z","timestamp":1741432069000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02668-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2668"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02668-z","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"21 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work obtained ethical approval from the Faculty of Medicine, Alexandria University (approval number 0107026) (IRB number: 00012098). This work was carried out following the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}